Abstract
A demonstration of the effectiveness of shorter therapy for deep venous thrombosis has been eagerly awaited at all levels of the cost-aware health care system. The study by Hull and colleagues (May 3 issue)* provides some affirmative evidence but should not be regarded as sufficient to recommend widespread changes in the standard of care.